Earnings Summary

Syros Pharmaceuticals Inc’s revenue jumped 107.06% since last year same period to $0.39Mn in the Q4 2023. On a quarterly growth basis, Syros Pharmaceuticals Inc has generated -89.74% fall in its revenue since last 3-months.

Syros Pharmaceuticals Inc’s net profit fell -333.49% since last year same period to $-64.38Mn in the Q4 2023. On a quarterly growth basis, Syros Pharmaceuticals Inc has generated -60.39% fall in its net profits since last 3-months.

Syros Pharmaceuticals Inc’s net profit margin fell -3206.92% since last year same period to -16679.79% in the Q4 2023. On a quarterly growth basis, Syros Pharmaceuticals Inc has generated -1463.15% fall in its net profit margins since last 3-months.

Syros Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.87 - a 23.68% jump from last quarter’s estimates.

Syros Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.87.

Syros Pharmaceuticals Inc’s earning per share (EPS) fell -1182.35% since last year same period to -2.18 in the Q4 2023. This indicates that the Syros Pharmaceuticals Inc has generated -1182.35% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Syros Pharmaceuticals Inc’s return on assets (ROA) stands at -0.38.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Syros Pharmaceuticals Inc’s return on equity (ROE) stands at -2.28.